US64125C1099 - Common Stock
92.71 +0.39 (+0.42%)
NEUROCRINE BIOSCIENCES INC
NASDAQ:NBIX (6/5/2023, 11:33:45 AM)
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find more growth stocks the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 1,200 full-time employees. The firm is focused on discovering and developing pharmaceuticals for the treatment of neurological, endocrine and psychiatric-based diseases and disorders. Its portfolio includes treatments for tardive dyskinesia, Parkinson’s disease, endometriosis and uterine fibroids. Its product pipeline includes INGREZZA (valbenazine), which provides a once-daily dosing treatment option for tardive dyskinesia and has three dosing options (40 milligrams (mg), 60 mg and 80 mg capsules); ONGENTYS (opicapone) is an adjunctive therapy to levodopa/carbidopa in patients with Parkinson’s disease; ORILISSA (elagolix) is used for the management of moderate to severe endometriosis pain in women. Its pipeline also includes DYSVAL (valbenazine), ORIAHNN (elagolix, estradiol, and norethindrone acetate and elagolix capsules), ALKINDI/ALKINDI SPRINKLE (hydrocortisone), and EFMODY (hydrocortisone modified-release hard capsules).
NEUROCRINE BIOSCIENCES INC
12780 El Camino Real
San Diego CALIFORNIA 92130
CEO: Kevin C. Gorman
/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented findings from a meta-analysis of three long-term studies evaluating INGREZZA®...
- Statistically Significant Improvement in Chorea Associated with Huntington's Disease Seen as Early as Week 2 - Chorea Improvement Supported by Statistically...
/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced findings from a post hoc analysis of two long-term studies (KINECT™ 3 and KINECT™...
Here you can normally see the latest stock twits on NBIX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.